Lipoprotein(a) metabolism

Current Opinion in Lipidology

Volumn 25, Issue 3, 2014, Pages 189-193

  Lamon Fava, Stefania ^a,b   Diffenderfer, Margaret R ^a   Marcovina, Santica M ^c  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Apo(a); apoB100; kinetics; lipoprotein(a); metabolism

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; ROSUVASTATIN; SCAVENGER RECEPTOR BI; TRIACYLGLYCEROL; SCARB1 PROTEIN, HUMAN; SCAVENGER RECEPTOR B;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; KIDNEY; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; THROMBOSIS; TREATMENT OUTCOME; GENE LOCUS; GENETICS; METABOLISM;

ANIMALIA;

APOLIPOPROTEIN B-100; APOPROTEIN(A); ATHEROSCLEROSIS; GENETIC LOCI; HUMANS; SCAVENGER RECEPTORS, CLASS B;

EID: 84900536315     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000070     Document Type: Review

References (39)

1. Berg K. A new serum type system in man-the Lp system. Acta pathol Microbiol Scand 1963; 59:369-382.
2. Utermann G, Web er W. Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett 1983; 154:357-361.
3. Gaubatz JW, Heideman C, Gotto AM Jr, et al. Human plasma lipoprotein [a]. Structural properties. J Biol Chem 1983; 258:4582-4589.
4. Frank SL, Klisak I, Sparkes RS, et al. The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen. Hum Genet 1988; 79:352-356.
5. Lawn RM, Schwartz K, Patthy L. Convergent evolution of apolipoprotein(a) in primates and hedgehog. Proc Natl Acad Sci U S A 1997; 94:11992-11997.
6. Seman LJ, Breckenridge WC. Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a). Biochem Cell Biol 1986; 64:999-1009.
7. Klezovitch O, Scanu AM. Heterogeneity of lipoprotein (a): Growing complexities. Curr Opin Lipidol 1995; 6:223-228.
8. Lamon -Fava S, Marcovina SM, Albers JJ, et al. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res 2011; 52:1181-1187.
9. Khera A V, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: An analysis from the JUPITER trial. Circulation 2013.
10. Marcovina SM, Albers JJ, Wij sman E, et al. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res 1996; 37:2569-2585.
11. Rader DJ, Cain W, Ikewaki K, et al. The in verse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994; 93:2758-2763.
12. Hopewell JC, Seedorf U, Farrall M, et al. Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med 2013.
13. Clarke R, Peden JF, Hopewell JC , et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361:2518-2528.
14. Erqou S, Kaptoge S, et al., Emerging Risk Factors Collaboration. Lipoprotein( a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302:412-423.
15. Albers JJ, Slee A, O ?Brien KD, et al. Relationship of apolipo proteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 2013; 62:1575-1579.
16. Maher VM, Brown BG, Marcovina SM, et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995; 274: 1771-1774.
17. Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol 2012; 60:722-729.
18. Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: A rationale for increased efforts to understand its pathophysio logy and develop targeted therapies. J Am Coll Cardiol 2012; 60:716-721.
19. Sotiriou SN, Orlova VV, Al-Fakhri N, et al. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J 2006; 20:559-561.
20. Morrisett JD,Gaubatz JW,Nava MN,et al, Metabolism of apo(a) and apo-B-100 in human lipoprotein(a). Med Sci Symp Ser, 1993, 2, 161-167.
21. Su W, Campos H, Judge H, et al. Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: Effect of postmenopausal estrogen replacement. J Clin Endocrinol Metab 1998; 83:3267-3276.
22. Demant T, Seeberg K, Bedynek A, Seidel D . The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: A kinetic study in humans. Atherosclerosis 2001; 157:325-339.
23. Jenner JL, Seman LJ, Millar JS, et al. The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings. Metabolism 2005; 54:361-369.
24. Frischmann ME, Kronenberg F, Trenkwalder E, et al. In vivo turnov er study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 2007; 71:1036-1043.
25. Nassir F, Bonen DK, Davidson NO. Apolipoprotein(a) synthesis and secretion from he patoma cells is coupled to triglyceride synthesis and secretion. J Biol Chem 1998; 273:17793-17800.
26. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglycerid e transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study. Lancet 2013; 381:40-46.
27. Menzel HJ, Dieplinger H, Lackner C, et al. Abetalipoproteinemia with an ApoB-100-lipoprotein(a) glycoprotein complex in plasma. Indication for an assembly defect. J Biol Chem 1990; 265:981-986.
28. Raal FJ, Santos RD, Blom DJ, et al. Mi pomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 375:998- 1006.
29. Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J 2013.
30. Sun H, Samarghandi A, Zhang N, et al. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol 2012; 32:1585-1595
31. Desai NR, Giugliano RP, Zhou J, et al. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of NCEP-ATP III LDL-C goals among high risk patients: An analysis from the LAPLACE-TIMI 57 trial. J Am Co ll Cardiol 2014; 63:430-433.
32. White AL, Rainwater DL, Hixson JE, et al. Intracellular processing of apo(a) in primary baboon hepatocytes. Chem Phys Lipids 1994; 67- 68:123-133.
33. Lobentanz EM, Krasznai K, Gruber A, et al. Intracellular metabolism of human apolipoprotein(a) in stably transfected Hep G2 cells. Biochemistry 1998; 37:5417-5425.
34. Frischmann ME, Ikewaki K, Trenkwalder E, et al. In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a). Atherosclerosis 2012; 225:322-327.
35. Rader DJ, Mann WA, Cain W, et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995; 95:1403-1408.
36. Niemeier A, Willnow T, Dieplinger H, et al. Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro. Arterioscler Thromb Vasc Biol 1999; 19:552-561.
37. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis 1996; 27:1-25.
38. Ikewaki K. In vivo kinetic studies to further understand pathogenesis of abnormal lipoprotein metabolism in chronic kidney disease. Clin Exp Nephrol 2013.
39. Yang XP, Amar MJ, Vaisman B, et al. Scavenger receptor-BI is a receptor for lipoprotein(a). J Lipid Res 2013; 54:2450-2457.